Shopping Cart 0
Cart Subtotal
AED 0

ViiV Healthcare Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 2753

Details

Summary

ViiV Healthcare Ltd (ViiV), formerly Glaxosmithkline Newco Ltd, a subsidiary of GlaxoSmithKline Plc, is a researcher and developer of HIV medicines. The company provides nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitor, protease inhibitors, and CCR5 antagonist for the treatment of AIDS. Its products include dolutegravir, zidovudine, fosamprenavi, maraviroc, abacavir, and nelfinavir and delavirdine mesylate. ViiV also offers various fellowship programs for primary care HIV specialists. The company partners with HIV community to provide education and support services to people with AIDS. It operates in Japan, the US, the Netherlands, the UK, Australia, Portugal and Belgium. ViiV is headquartered in Brentford, the UK.

ViiV Healthcare Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 11

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 12

ViiV Healthcare To Acquire Integrase Inhibitor Portfolio Of Shionogi 13

Partnerships 14

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 14

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 15

Licensing Agreements 16

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 16

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 16

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 17

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 18

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 19

ViiV Healthcare Announces Licensing Agreement For Celsentri 20

ViiV Healthcare Ltd-Key Competitors 21

Key Employees 22

Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Corporate Communications 24

Dec 05, 2016: Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him 24

Clinical Trials 25

Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir 25

Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment 26

Other Significant Developments 27

Apr 08, 2016: Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28


List Of Figure

List of Figures

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9


List Of Table

List of Tables

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Key Facts 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 11

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 12

ViiV Healthcare To Acquire Integrase Inhibitor Portfolio Of Shionogi 13

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 14

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 15

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 16

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 16

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 17

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 18

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 19

ViiV Healthcare Announces Licensing Agreement For Celsentri 20

ViiV Healthcare Ltd, Key Competitors 21

ViiV Healthcare Ltd, Key Employees 22

ViiV Healthcare Ltd, Other Locations 23

ViiV Healthcare Ltd, Subsidiaries 23

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

ViiV Healthcare Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

ViiV Healthcare Ltd (ViiV), formerly Glaxosmithkline Newco Ltd, a subsidiary of GlaxoSmithKline Plc, is a researcher and developer of HIV medicines. The company provides nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitor, protease inhibitors, and CCR5 antagonist for the treatment of AIDS. Its products include dolutegravir, zidovudine, fosamprenavi, maraviroc, abacavir, and nelfinavir and delavirdine mesylate. ViiV also offers various fellowship programs for primary care HIV specialists. The company partners with HIV community to provide education and support services to people with AIDS. It operates in Japan, the US, the Netherlands, the UK, Australia, Portugal and Belgium. ViiV is headquartered in Brentford, the UK.

ViiV Healthcare Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 11

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 12

ViiV Healthcare To Acquire Integrase Inhibitor Portfolio Of Shionogi 13

Partnerships 14

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 14

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 15

Licensing Agreements 16

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 16

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 16

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 17

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 18

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 19

ViiV Healthcare Announces Licensing Agreement For Celsentri 20

ViiV Healthcare Ltd-Key Competitors 21

Key Employees 22

Locations And Subsidiaries 23

Head Office 23

Other Locations & Subsidiaries 23

Recent Developments 24

Corporate Communications 24

Dec 05, 2016: Dominique Limet to step down as CEO of ViiV Healthcare; Deborah Waterhouse to succeed him 24

Clinical Trials 25

Feb 24, 2016: ViiV Healthcare announces first phase II HIV prevention study results for investigational long-acting injectable cabotegravir 25

Feb 23, 2016: ViiV Healthcare announces phase II study results for first two drug, long-acting injectable regimen for HIV-1 treatment 26

Other Significant Developments 27

Apr 08, 2016: Global partnership launches new programme with goal to save the lives of thousands of children affected by HIV in Lesotho 27

Appendix 28

Methodology 28

About GlobalData 28

Contact Us 28

Disclaimer 28


List Of Figure

List of Figures

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9


List Of Table

List of Tables

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Key Facts 1

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

ViiV Healthcare Ltd, Deals By Therapy Area, 2011 to YTD 2017 8

ViiV Healthcare Ltd, Medical Devices Deals, 2011 to YTD 2017 9

ViiV Healthcare Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ViiV Healthcare Acquires HIV R&D Assets of Bristol-Myers Squibb for up to USD835 Million 11

ViiV Healthcare Acquires HIV Research Assets of Bristol-Myers Squibb for USD620 Million 12

ViiV Healthcare To Acquire Integrase Inhibitor Portfolio Of Shionogi 13

ViiV Healthcare Enters into Agreement with Janssen Sciences Ireland UC 14

ViiV Healthcare Enters into Co-Development Agreement with Janssen R&D Ireland 15

Mylan Enters into Licensing Agreement with MPP and ViiV Healthcare for Dolutegravir 16

Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 16

Laurus Labs Enters into Licensing Agreement with MPP and ViiV Healthcare For Dolutegravir 17

Medicines Patent Pool Extends Licensing Agreement with ViiV Healthcare 18

ViiV Healthcare Enters Into Licensing Agreement With Medicines Patent Pool For Epzicom 19

ViiV Healthcare Announces Licensing Agreement For Celsentri 20

ViiV Healthcare Ltd, Key Competitors 21

ViiV Healthcare Ltd, Key Employees 22

ViiV Healthcare Ltd, Other Locations 23

ViiV Healthcare Ltd, Subsidiaries 23

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

ViiV Healthcare Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.